AYJ Stock Chart & Stats
€2.56
€0.01(0.61%)
At close: 4:00 PM EST
€2.56
€0.01(0.61%)
Day’s Range― - ―
52-Week Range€2.14 - €5.31
Previous CloseN/A
Volume18.49K
Average Volume (3M)67.23K
Market Cap
€413.24M
Enterprise Value€545.93M
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume44,445
30 Day Avg. Volume67,228
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€153.95M
Bulls Say, Bears Say
Bulls Say
Lyme Vaccine (VLA15) Phase III Efficacy & Pfizer Regulatory PathVLA15's positive Phase III efficacy and Pfizer's intent to file give Valneva a structurally differentiated asset in a 30‑year void. With broad serotype coverage for North America and Europe and a large addressable population, a Pfizer-led regulatory path materially raises the probability of a durable, partner‑backed commercial franchise and recurring revenue potential once approved.
Manufacturing Network Expansion And Non‑U.S. ApprovalsCompletion of the Almeida transfer and non‑U.S. approvals diversifies Valneva's supply base and reduces single‑site dependency. A broader manufacturing network and local partnerships improve long‑term supply reliability, support access strategies in endemic markets, and lower strategic execution risk for future commercial rollouts and partnerships.
Restructuring To Materially Cut Operating ExpensesA formal program targeting a large opex reduction is a structural lever to extend runway and improve operating leverage. If executed, sustained lower fixed costs can reduce cash burn, preserve optionality for late‑stage programs and commercial launches, and improve path to positive operating cash flow irrespective of short‑term travel demand volatility.
Bears Say
Sustained Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow indicates the business consumes material cash to fund operations and development. This structural cash burn increases reliance on external financing or dilutive measures, limits discretionary investment in commercialization or manufacturing scale‑up, and elevates refinancing risk over the next several quarters if margins and revenues do not recover.
High Leverage And Shrinking Equity BaseAn elevated debt-to-equity ratio combined with a reduced equity cushion tightens financial flexibility. Continued losses against this capital structure raise the probability of costly refinancing, covenant pressure or dilution. High leverage also increases sensitivity to interest, FX swings and restricts the company's capacity to fund late‑stage launches or unforeseen regulatory remediation.
Manufacturing Setbacks Driving Margin DeteriorationSharp declines in product gross margins driven by failed batches, idle costs and provisions reflect structural manufacturing execution and quality issues. Persistent higher COGS undermines product economics, hinders margin recovery even with stable sales, and can constrain competitive pricing and profitability of both legacy vaccines and future launches until operational reliability is restored.
Valneva News
AYJ FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.14 and its highest was €5.31 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €413.24M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 30 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went up 0.038%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in DE:AYJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.
Technical Analysis
Options Prices
Currently, No data available
---